Salvage therapy for prostate cancer after radical prostatectomy

Nicholas G. Zaorsky, Jeremie Calais, Stefano Fanti, Derya Tilki, Tanya Dorff, Daniel E. Spratt, Amar U. Kishan

Research output: Contribution to journalReview articlepeer-review

23 Scopus citations


More than 40% of men with intermediate-risk or high-risk prostate cancer will experience a biochemical recurrence after radical prostatectomy. Clinical guidelines for the management of these patients largely focus on the use of salvage radiotherapy with or without systemic therapy. However, not all patients with biochemical recurrence will go on to develop metastases or die from their disease. The optimal pre-salvage therapy investigational workup for patients who experience biochemical recurrence should, therefore, include novel techniques such as PET imaging and genomic analysis of radical prostatectomy specimen tissue, as well as consideration of more traditional clinical variables such as PSA value, PSA kinetics, Gleason score and pathological stage of disease. In patients without metastatic disease, the only known curative intervention is salvage radiotherapy but, given the therapeutic burden of this treatment, importance must be placed on accurate timing of treatment, radiation dose, fractionation and field size. Systemic therapy also has a role in the salvage setting, both concurrently with radiotherapy and as salvage monotherapy.

Original languageEnglish (US)
Pages (from-to)643-668
Number of pages26
JournalNature Reviews Urology
Issue number11
StatePublished - Nov 2021

All Science Journal Classification (ASJC) codes

  • Urology


Dive into the research topics of 'Salvage therapy for prostate cancer after radical prostatectomy'. Together they form a unique fingerprint.

Cite this